Several studies in vivo indicate platelet activation in migraine, as reflected by increased plasma concentrations of platelet secretory products. In vitro data on platelet secretion are scant, which prompted an investigation into agonistinduced platelet aggregation and secretion in platelets from patients with migraine. Sixty two patients with migraine with aura (MA) and 41 with migraine without aura (MwA) were studied during a headache-free phase, together with 26 healthy controls. Platelet aggregation and secretion in platelet-rich plasma were induced by collagen and platelet activating factor (PAF). Serotonin was measured by high performance liquid chromatography and platelet factor 4 (PF4) with an enzyme immunoassay kit. There were no significant aberrations in platelet aggregation in those with migraine compared with healthy controls. The platelet PF4 secretion induced by PAF-(1.-0 and 0X1 uM) was-increased in MwA (p < 0.05, p < 0.0001) compared with controls, and there was a similar trend in MA (NS, p < 0.01). By contrast, the PF4 secretion induced by collagen (0.5 and 2 0 ,gIml) was reduced in MA (p < 0-01 and p < 0.05). Further, the MA group exhibited increased basal intraplatelet serotonin concentrations (p < 0-0001) and increased serotonin secretion induced by both concentrations of collagen (p < 0-0001) and PAF (p < 0-001). The data indicate an abnormal platelet a-granule secretion in those with migraine, and focus attention on PAF as a possible factor contributing to the platelet activation associated with migraine. The increased platelet content and secretion of serotonin was specific to MA, and may reflect different serotonin turnover in the two clinical migraine types.
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Several studies in vivo indicate platelet activation in migraine, as reflected by increased plasma concentrations of platelet secretory products. In vitro data on platelet secretion are scant, which prompted an investigation into agonistinduced platelet aggregation and secretion in platelets from patients with migraine. Sixty two patients with migraine with aura (MA) and 41 with migraine without aura (MwA) were studied during a headache-free phase, together with 26 healthy controls. Platelet aggregation and secretion in platelet-rich plasma were induced by collagen and platelet activating factor (PAF). Serotonin was measured by high performance liquid chromatography and platelet factor 4 (PF4) with an enzyme immunoassay kit. There were no significant aberrations in platelet aggregation in those with migraine compared with healthy controls. The platelet PF4 secretion induced by PAF-(1.-0 and 0X1 uM) was-increased in MwA (p < 0.05, p < 0.0001) compared with controls, and there was a similar trend in MA (NS, p < 0.01). By contrast, the PF4 secretion induced by collagen (0.5 and 2 0 ,gIml) was reduced in MA (p < 0-01 and p < 0.05). Further, the MA group exhibited increased basal intraplatelet serotonin concentrations (p < 0-0001) and increased serotonin secretion induced by both concentrations of collagen (p < 0-0001) and PAF (p < 0-001). The data indicate an abnormal platelet a-granule secretion in those with migraine, and focus attention on PAF as a possible factor contributing to the platelet activation associated with migraine. The increased platelet content and secretion of serotonin was specific to MA, and may reflect different serotonin turnover in the two clinical migraine types. (7 Neurol Neurosurg Psychiatry 1994;57:557-561) Platelet activation in association with migraine was first suggested by findings in the early 1960s. These were indicative of serotonin release from circulating platelets during the attack,' thereby initiating the still ongoing discussion on the role of platelets and serotonin in migraine. Due to the important role attributed to serotonin, platelet studies in migraine have focused; for the most part, on the serotonin-related aspects of platelet function and metabolism.
Other reflections of in vivo platelet activation in migraine are increased plasma concentrations of the platelet a-granule proteins, fl-thromboglobulin (Jf-TG) and platelet factor 4 (PF4).2 Although these concentrations are also raised in the headache-free periods, the increases are apparently particularly pronounced in association with attacks, indicating that the postulated serotonin release from dense granules during migraine attacks is parallelled by a-granule secretion.
Despite this evidence in vivo of platelet hypersecretion in migraine, there have been few in vitro studies of platelet secretion. Often, platelet aggregation has been used as the solitary measure of platelet function. Coupled measurements of agonist-induced platelet aggregation-and the secretion from dense and a-granules, could increase knowledge about factors causing platelet activation in migraine, and add to the understanding of the possible role of platelets in the pathophysiology of migraine attacks. Accordingly, we determined aggregation and secretion, induced by collagen and platelet activating factor (PAF), in platelets from subjects with migraine with aura (MA) and migraine without aura (MwA) during a headache-free phase. Our data thus indicate an aberrant platelet a-granule secretion in platelets from patients with migraine, and the divergent platelet responses induced by the two agonists, PAF and collagen, suggest an abnormality in transformation of the cellular signal. It may seem abstruse that the other platelet responses did not follow the same pattern, as they are generally considered to be elicited according to the potency of the stimulus in the order: aggregation, dense granule secretion, and a-granule secretion.6 Platelet responses do not, however, always occur in this sequential order,7-9 and furthermore the proportions between dense and a-granule secretion may vary at different agonist concentrations. 10 Our present finding of a specific platelet a-granule hypersecretion in response to PAF is in accordance with other findings in patients with migraine of an enhanced increase in platelet cytoplasmic ionised calcium ([Ca2+],) on stimulation with PAF, but not collagen." Thus, the platelet hypersecretion from a-granules induced by PAF may, at least in part, be connected to abberrant intracellular calcium transients and perhaps an enhancement in the coupling between the phosphatidylinositol cycle and Ca2 + mobilisation. This assumption is not in controversy with the diverse platelet response to collagen, as collagen only mobilises Ca2 + weakly. '2 The mechanisms behind the impairment of the collagen-induced platelet a-granule secretion that we found solely in platelets from the MA group remain unclear. One possibility is that it may involve an anomaly of the protein kinase C pathway associated with collageninduced secretion. 12 It is not inconceivable that anomalies at different steps of the transformation of the cellular signal may have a different impact on the secretion from the two granule types, as the secretion from the dense and the a-granules has been shown to differ with regard to dependence of Ca' + and protein kinase C.'0 It seems less likely that this impairment of a-granule secretion is due to a decreased amount of a-granular material, because it was specific for collagen. Furthermore, it has been shown that the number of a-granules is not decreased in patients with migraine." 3 We failed to find any significant parallel changes in platelet aggregation induced by collagen or PAF. However, as quantitative measurement of platelet secretion is more sensitive than determination of platelet aggregation, it is possible that we may have failed to detect a parallel increase in platelet aggregation. Other studies have emphasised abnormalities in platelet aggregation in response to PAF in patients with migraine,'415 and the issue needs further investigation.
The present findings of a specific platelet hypersensitivity to PAF in migraine, focuses attention on PAF as a possible contributor to platelet activation in migraine. To our knowledge, PAF concentrations have not been measured in migraineurs, but it is conceivable that migraine attacks may be associated with locally increased concentrations of PAF. There is evidence suggesting that the formation of PAF is stimulated by substance P16; a peptide that is released from the trigeminovascular system into the extracerebral circulation during migraine attacks. ' The increased serotonin secretion found in platelets from patients with MA, was associated with similarly increased basal intraplatelet serotonin concentration as also indicated by our previous data.13 Hence, the increased platelet serotonin secretion in MA seems to be due to increased platelet serotonin content rather than a hypersecretory response itself.
Our present results confirm previous findings that in MA there is an increased number of platelet dense granules, which contain the secretable pool of platelet serotonin. 13 concentra- tions in both migraine types. A factor that may in part explain why our findings differ is that we took into account variations in platelet serotonin during the menstrual cycle.
The diverse patterns of platelet content and secretion of serotonin in the two migraine types may be a reflection of different serotonin turnover, possibly also in the CNS. An increased serotonin turnover in MA may be related to the lower frequency, duration, and pain intensity of attacks reported in this migraine type23; also demonstrated in our patients (table 1) . Further, considering that serotonin infusions have been shown to relieve migraine24 an enhanced serotonin release from platelets may alleviate the MA attack.
